BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21627019)

  • 1. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
    Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
    Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study.
    Kalinowski M; Dressler M; König A; El-Sheik M; Rinke A; Höffken H; Gress TM; Arnold R; Klose KJ; Wagner HJ
    Digestion; 2009; 79(3):137-42. PubMed ID: 19307736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience.
    İnce S; Karaman B; Alagoz E; Karadurmuş N; Şan H; Erçin CN; Arslan N
    J Gastrointest Cancer; 2017 Sep; 48(3):281. PubMed ID: 28634669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization.
    Doyle PW; Workman CS; Grice JV; McGonigle TW; Huang S; Borgmann AJ; Baker JC; Taylor JE; Brown DB
    J Vasc Interv Radiol; 2024 May; 35(5):699-708. PubMed ID: 37871833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
    Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.
    Kuei A; Saab S; Cho SK; Kee ST; Lee EW
    World J Gastroenterol; 2015 Jul; 21(27):8271-83. PubMed ID: 26217079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
    Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
    World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.
    Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M;
    In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.
    Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH
    J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
    Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong CY; Qing F; Savin M; Campbell J; Gates VL; Sherpa KM; Lewandowski RJ; Nagle C; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1101-6. PubMed ID: 16105922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
    Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
    Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
    Ebbers SC; van Roekel C; Braat MNGJA; Barentsz MW; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1700-1710. PubMed ID: 34873638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis.
    Frilling A; Clift AK; Braat AJAT; Alsafi A; Wasan HS; Al-Nahhas A; Thomas R; Drymousis P; Habib N; Tait PN
    HPB (Oxford); 2019 Jul; 21(7):773-783. PubMed ID: 30733049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.